Cytokinetics traded at $64.66 this Friday September 25th, decreasing $1.00 or 1.52 percent since the previous trading session. Looking back, over the last four weeks, Cytokinetics lost 18.36 percent. Over the last 12 months, its price rose by 28.29 percent. Looking ahead, we forecast Cytokinetics to be priced at 67.30 by the end of this quarter and at 63.05 in one year, according to Trading Economics global macro models projections and analysts expectations.
Cytokinetics, Incorporated is a late-stage biopharmaceutical company that is focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. The Company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. The Company is conducting METEORIC-HF, a second Phase III clinical trial of omecamtiv mecarbil. It is also developing aficamten, a cardiac myosin inhibitor, for the potential treatment of HCM. The Company also conducts research and development on novel treatments for disorders involving muscle function beyond muscle contractility. The Company’s lead drug candidates in clinical development are omecamtiv mecarbil, a cardiac myosin activator; CK-136, a cardiac troponin activator; reldesemtiv, a fast-skeletal muscle troponin activator (FSTA) and CK-3773274 (CK-274), a cardiac myosin inhibitor.